JP2014502268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502268A5 JP2014502268A5 JP2013540331A JP2013540331A JP2014502268A5 JP 2014502268 A5 JP2014502268 A5 JP 2014502268A5 JP 2013540331 A JP2013540331 A JP 2013540331A JP 2013540331 A JP2013540331 A JP 2013540331A JP 2014502268 A5 JP2014502268 A5 JP 2014502268A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- sulfonamide
- pyridine
- thiazol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- -1 methoxy, phenyl core Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 claims 2
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- YHVNROMKNKOXHD-UHFFFAOYSA-N N-[1-(6-chloro-1,3-benzothiazol-2-yl)piperidin-4-yl]oxy-3-phenylpyridine-2-sulfonamide Chemical compound C1(=CC=CC=C1)C=1C(=NC=CC=1)S(=O)(=O)NOC1CCN(CC1)C=1SC2=C(N=1)C=CC(=C2)Cl YHVNROMKNKOXHD-UHFFFAOYSA-N 0.000 claims 1
- RBXLTORBUCHVBO-UHFFFAOYSA-N N1=C(C=CC=C1)S(=O)(=O)NC1(CC=CC=C1)OC1CCNC(C1)C=1OC2=C(N1)C=CC(=C2)Cl Chemical compound N1=C(C=CC=C1)S(=O)(=O)NC1(CC=CC=C1)OC1CCNC(C1)C=1OC2=C(N1)C=CC(=C2)Cl RBXLTORBUCHVBO-UHFFFAOYSA-N 0.000 claims 1
- MGLBSXFETBFWIT-UHFFFAOYSA-N N1=C(C=CC=C1)S(=O)(=O)NC1(CC=CC=C1)OC1CCNCC1C=1OC2=C(N1)C(=CC=C2)C(C)(C)C Chemical compound N1=C(C=CC=C1)S(=O)(=O)NC1(CC=CC=C1)OC1CCNCC1C=1OC2=C(N1)C(=CC=C2)C(C)(C)C MGLBSXFETBFWIT-UHFFFAOYSA-N 0.000 claims 1
- AUCJMIWMOYNWAS-UHFFFAOYSA-N N1=C(C=CC=C1)S(=O)(=O)NC1=CC=C(C=C1)C(=O)N1CCNCC1C=1SC2=C(N1)C(=CC=C2)F Chemical compound N1=C(C=CC=C1)S(=O)(=O)NC1=CC=C(C=C1)C(=O)N1CCNCC1C=1SC2=C(N1)C(=CC=C2)F AUCJMIWMOYNWAS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- AZSLYKFHYPJTJS-UHFFFAOYSA-N [NH-]S(C1=NC=CC=C1C(C=CC=C1)=C1C(N(CC1)CCN1C1=NC(C=CC(Br)=C2)=C2S1)=O)(=O)=O.[Li+] Chemical compound [NH-]S(C1=NC=CC=C1C(C=CC=C1)=C1C(N(CC1)CCN1C1=NC(C=CC(Br)=C2)=C2S1)=O)(=O)=O.[Li+] AZSLYKFHYPJTJS-UHFFFAOYSA-N 0.000 claims 1
- HWXWKKJZWGZDJU-UHFFFAOYSA-M [Na+].BrC1=CC=C2N=C(SC2=C1)N1CCN(CC1)C(=O)C1=C([N-]S(=O)(=O)C2=NC=CC=C2)C=CC=C1 Chemical compound [Na+].BrC1=CC=C2N=C(SC2=C1)N1CCN(CC1)C(=O)C1=C([N-]S(=O)(=O)C2=NC=CC=C2)C=CC=C1 HWXWKKJZWGZDJU-UHFFFAOYSA-M 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 210000001008 atrial appendage Anatomy 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- FTCLFVJBYJJMOU-UHFFFAOYSA-N n-[2-[1-(1,3-benzothiazol-2-yl)piperidin-4-yl]oxyphenyl]pyridine-2-sulfonamide Chemical compound C=1C=CC=C(OC2CCN(CC2)C=2SC3=CC=CC=C3N=2)C=1NS(=O)(=O)C1=CC=CC=N1 FTCLFVJBYJJMOU-UHFFFAOYSA-N 0.000 claims 1
- KGWRAHTZPPVCNC-UHFFFAOYSA-N n-[2-[1-(5-chloro-1,3-benzoxazol-2-yl)piperidin-4-yl]oxyphenyl]pyridine-2-sulfonamide Chemical compound N=1C2=CC(Cl)=CC=C2OC=1N(CC1)CCC1OC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 KGWRAHTZPPVCNC-UHFFFAOYSA-N 0.000 claims 1
- RMDVJMZBLGSURX-UHFFFAOYSA-N n-[2-[1-(6-bromo-1,3-benzothiazol-2-yl)piperidin-4-yl]oxyphenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(Br)=CC=C2N=C1N(CC1)CCC1OC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 RMDVJMZBLGSURX-UHFFFAOYSA-N 0.000 claims 1
- PQUJIYDNCVIJHF-UHFFFAOYSA-N n-[2-[1-(6-methyl-1,3-benzoxazol-2-yl)piperidin-4-yl]oxyphenyl]pyridine-2-sulfonamide Chemical compound O1C2=CC(C)=CC=C2N=C1N(CC1)CCC1OC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 PQUJIYDNCVIJHF-UHFFFAOYSA-N 0.000 claims 1
- JHMDXRSCMBWCAH-UHFFFAOYSA-N n-[2-[4-(4-methyl-1,3-benzothiazol-2-yl)-1,4-diazepane-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound N=1C=2C(C)=CC=CC=2SC=1N(CC1)CCCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 JHMDXRSCMBWCAH-UHFFFAOYSA-N 0.000 claims 1
- ADXGZLMYJHQLJG-UHFFFAOYSA-N n-[2-[4-(4-methyl-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound N=1C=2C(C)=CC=CC=2SC=1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 ADXGZLMYJHQLJG-UHFFFAOYSA-N 0.000 claims 1
- PGMZZQSBSZSDSF-UHFFFAOYSA-N n-[2-[4-(6-bromo-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]-6-methylpyridine-2-sulfonamide;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC(S(=O)(=O)NC=2C(=CC=CC=2)C(=O)N2CCN(CC2)C=2SC3=CC(Br)=CC=C3N=2)=N1 PGMZZQSBSZSDSF-UHFFFAOYSA-N 0.000 claims 1
- AQQKTRWAWUIXKC-UHFFFAOYSA-N n-[2-[4-(6-bromo-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(Br)=CC=C2N=C1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 AQQKTRWAWUIXKC-UHFFFAOYSA-N 0.000 claims 1
- CHSGLAMFRYTPKF-UHFFFAOYSA-N n-[2-[4-(6-bromo-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(=O)N3CCN(CC3)C3=NC4=CC=C(C=C4S3)Br)=CC=CC2=C1 CHSGLAMFRYTPKF-UHFFFAOYSA-N 0.000 claims 1
- LAEYSTYZGLGKBE-UHFFFAOYSA-N n-[2-[4-(6-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide;hydrochloride Chemical compound Cl.S1C2=CC(Cl)=CC=C2N=C1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 LAEYSTYZGLGKBE-UHFFFAOYSA-N 0.000 claims 1
- GKZUZTODSKKVLP-UHFFFAOYSA-N n-[2-[4-(6-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(=O)N3CCN(CC3)C3=NC4=CC=C(C=C4S3)Cl)=CC=CC2=C1 GKZUZTODSKKVLP-UHFFFAOYSA-N 0.000 claims 1
- BLJDLAIEKBEZBH-UHFFFAOYSA-N n-[2-[4-(6-chloro-1,3-benzoxazol-2-yl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(=O)N3CCN(CC3)C3=NC4=CC=C(C=C4O3)Cl)=CC=CC2=C1 BLJDLAIEKBEZBH-UHFFFAOYSA-N 0.000 claims 1
- XETPZJGILMXLCR-UHFFFAOYSA-N n-[2-[4-(7-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound S1C=2C(Cl)=CC=CC=2N=C1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 XETPZJGILMXLCR-UHFFFAOYSA-N 0.000 claims 1
- VPQNZNHSRCYEJF-UHFFFAOYSA-N n-[2-[4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound N=1C2=CC(C(F)(F)F)=CC=C2SC=1N(CC1)CCN1C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 VPQNZNHSRCYEJF-UHFFFAOYSA-N 0.000 claims 1
- VLPMAOQQURVSNS-UHFFFAOYSA-N n-[2-[4-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(=O)N3CCN(CC3)C3=NC4=CC=C(C=C4S3)OC(F)(F)F)=CC=CC2=C1 VLPMAOQQURVSNS-UHFFFAOYSA-N 0.000 claims 1
- VXTMDNUGGBANEZ-UHFFFAOYSA-N n-[2-[[1-(1,3-benzothiazol-2-yl)pyrrolidin-3-yl]methoxy]phenyl]pyridine-2-sulfonamide Chemical compound C=1C=CC=C(OCC2CN(CC2)C=2SC3=CC=CC=C3N=2)C=1NS(=O)(=O)C1=CC=CC=N1 VXTMDNUGGBANEZ-UHFFFAOYSA-N 0.000 claims 1
- UKYIUMLFJHIALD-UHFFFAOYSA-N n-[2-[[1-(4-methoxy-1,3-benzothiazol-2-yl)pyrrolidin-3-yl]methoxy]phenyl]pyridine-2-sulfonamide Chemical compound N=1C=2C(OC)=CC=CC=2SC=1N(C1)CCC1COC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 UKYIUMLFJHIALD-UHFFFAOYSA-N 0.000 claims 1
- FWKRHEQNUAHZOB-UHFFFAOYSA-N n-[2-[[1-(4-methyl-1,3-benzothiazol-2-yl)pyrrolidin-3-yl]methoxy]phenyl]pyridine-2-sulfonamide Chemical compound N=1C=2C(C)=CC=CC=2SC=1N(C1)CCC1COC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 FWKRHEQNUAHZOB-UHFFFAOYSA-N 0.000 claims 1
- HSCTZILYCPRWKA-UHFFFAOYSA-N n-[2-[[1-(6-chloro-1,3-benzothiazol-2-yl)pyrrolidin-3-yl]methoxy]phenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(Cl)=CC=C2N=C1N(C1)CCC1COC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 HSCTZILYCPRWKA-UHFFFAOYSA-N 0.000 claims 1
- QZTXJRUCNBJKHI-UHFFFAOYSA-N n-[2-[[1-(6-fluoro-1,3-benzothiazol-2-yl)pyrrolidin-3-yl]methoxy]phenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(F)=CC=C2N=C1N(C1)CCC1COC1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 QZTXJRUCNBJKHI-UHFFFAOYSA-N 0.000 claims 1
- HQUPVOAZJDPSBO-UHFFFAOYSA-N n-[3-[4-(6-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]-6-methylpyridine-2-sulfonamide Chemical compound CC1=CC=CC(S(=O)(=O)NC=2C=C(C=CC=2)C(=O)N2CCN(CC2)C=2SC3=CC(Cl)=CC=C3N=2)=N1 HQUPVOAZJDPSBO-UHFFFAOYSA-N 0.000 claims 1
- PRZNECJSFLHDEH-UHFFFAOYSA-N n-[3-[4-(6-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(Cl)=CC=C2N=C1N(CC1)CCN1C(=O)C(C=1)=CC=CC=1NS(=O)(=O)C1=CC=CC=N1 PRZNECJSFLHDEH-UHFFFAOYSA-N 0.000 claims 1
- GHYHGSNORYNIRO-UHFFFAOYSA-N n-[3-[4-(6-chloro-1,3-benzoxazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound O1C2=CC(Cl)=CC=C2N=C1N(CC1)CCN1C(=O)C(C=1)=CC=CC=1NS(=O)(=O)C1=CC=CC=N1 GHYHGSNORYNIRO-UHFFFAOYSA-N 0.000 claims 1
- TZABFPVQEOIMCQ-UHFFFAOYSA-N n-[4-[4-(6-chloro-1,3-benzothiazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound S1C2=CC(Cl)=CC=C2N=C1N(CC1)CCN1C(=O)C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=N1 TZABFPVQEOIMCQ-UHFFFAOYSA-N 0.000 claims 1
- ZQNODSHXXVSTIH-UHFFFAOYSA-N n-[4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound O1C2=CC(Cl)=CC=C2N=C1N(CC1)CCN1C(=O)C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=N1 ZQNODSHXXVSTIH-UHFFFAOYSA-N 0.000 claims 1
- YOFGQVREJHTFCI-UHFFFAOYSA-N n-[4-[4-(6-fluoro-1,3-benzoxazol-2-yl)piperazine-1-carbonyl]phenyl]pyridine-2-sulfonamide Chemical compound O1C2=CC(F)=CC=C2N=C1N(CC1)CCN1C(=O)C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=N1 YOFGQVREJHTFCI-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- HPLIITOVMALJLX-UHFFFAOYSA-N potassium pyridin-2-ylsulfonylazanide Chemical compound [K+].N1=C(C=CC=C1)S(=O)(=O)[NH-] HPLIITOVMALJLX-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1059634A FR2967674B1 (fr) | 2010-11-23 | 2010-11-23 | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| FR1059634 | 2010-11-23 | ||
| PCT/EP2011/070736 WO2012069503A1 (en) | 2010-11-23 | 2011-11-23 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502268A JP2014502268A (ja) | 2014-01-30 |
| JP2014502268A5 true JP2014502268A5 (enExample) | 2014-11-20 |
| JP5837085B2 JP5837085B2 (ja) | 2015-12-24 |
Family
ID=44246390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540331A Expired - Fee Related JP5837085B2 (ja) | 2010-11-23 | 2011-11-23 | ヘテロアリールスルホンアミド誘導体、それらの製造およびヒト治療におけるそれらの応用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8846930B2 (enExample) |
| EP (1) | EP2643318A1 (enExample) |
| JP (1) | JP5837085B2 (enExample) |
| KR (1) | KR101838326B1 (enExample) |
| CN (1) | CN103209980B (enExample) |
| AR (1) | AR083903A1 (enExample) |
| AU (1) | AU2011333772B2 (enExample) |
| BR (1) | BR112013012615A2 (enExample) |
| CA (1) | CA2817531A1 (enExample) |
| FR (1) | FR2967674B1 (enExample) |
| IL (1) | IL226495A (enExample) |
| MA (1) | MA34658B1 (enExample) |
| MX (1) | MX352396B (enExample) |
| MY (1) | MY168283A (enExample) |
| NZ (1) | NZ610700A (enExample) |
| RU (1) | RU2582995C2 (enExample) |
| TW (1) | TWI576106B (enExample) |
| UA (1) | UA109295C2 (enExample) |
| WO (1) | WO2012069503A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597379A (en) | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| WO2012151452A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
| PH12017501176B1 (en) | 2011-05-03 | 2023-03-08 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CN105705495A (zh) * | 2013-10-17 | 2016-06-22 | 巴斯夫欧洲公司 | 制备取代靛红酸酐化合物及其衍生物的方法 |
| WO2015095111A1 (en) * | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Diazepane orexin receptor antagonists |
| CN104292179A (zh) * | 2014-10-19 | 2015-01-21 | 湖南华腾制药有限公司 | 一种2-氯苯并[d]恶唑-5-甲醛的制备方法 |
| FR3029112A1 (fr) * | 2014-12-02 | 2016-06-03 | Pf Medicament | Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique |
| SI3307271T1 (sl) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals, Inc. | Postopki za uporabo aktivatorjev piruvat kinaze |
| EP3601273B1 (en) * | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN107556266B (zh) * | 2017-09-12 | 2021-04-23 | 华南农业大学 | 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用 |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| CN113200934B (zh) * | 2021-05-18 | 2022-05-31 | 郑州大学 | 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用 |
| CN113912595B (zh) * | 2021-10-12 | 2024-03-15 | 中国药科大学 | 一类含有噻唑或噻二唑结构的化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149700A (en) * | 1990-05-30 | 1992-09-22 | American Home Products Corporation | Substituted arylsulfonamides and benzamides |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| ATE430142T1 (de) * | 2004-12-09 | 2009-05-15 | Hoffmann La Roche | Phenylpiperazin-methanon-derivate |
| EP1902051A1 (en) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007023882A1 (ja) * | 2005-08-26 | 2007-03-01 | Shionogi & Co., Ltd. | Ｐｐａｒアゴニスト活性を有する誘導体 |
| WO2009055357A1 (en) * | 2007-10-25 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Diazepane compounds which modulate the cb2 receptor |
| CA2727780A1 (en) * | 2008-06-13 | 2009-12-17 | Bionomics Limited | Novel potassium channel blockers and uses thereof |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| CN101503392B (zh) * | 2009-03-31 | 2010-12-29 | 中国药科大学 | 芳甲胺类化合物、其制备方法及其医药用途 |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| NZ597379A (en) * | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
-
2010
- 2010-11-23 FR FR1059634A patent/FR2967674B1/fr active Active
-
2011
- 2011-11-03 TW TW100140099A patent/TWI576106B/zh not_active IP Right Cessation
- 2011-11-17 AR ARP110104287A patent/AR083903A1/es unknown
- 2011-11-23 AU AU2011333772A patent/AU2011333772B2/en not_active Ceased
- 2011-11-23 CA CA2817531A patent/CA2817531A1/en not_active Abandoned
- 2011-11-23 CN CN201180055123.XA patent/CN103209980B/zh not_active Expired - Fee Related
- 2011-11-23 JP JP2013540331A patent/JP5837085B2/ja not_active Expired - Fee Related
- 2011-11-23 WO PCT/EP2011/070736 patent/WO2012069503A1/en not_active Ceased
- 2011-11-23 EP EP11785690.6A patent/EP2643318A1/en not_active Withdrawn
- 2011-11-23 US US13/822,406 patent/US8846930B2/en not_active Expired - Fee Related
- 2011-11-23 RU RU2013126251/04A patent/RU2582995C2/ru not_active IP Right Cessation
- 2011-11-23 BR BR112013012615A patent/BR112013012615A2/pt not_active IP Right Cessation
- 2011-11-23 MX MX2013005734A patent/MX352396B/es active IP Right Grant
- 2011-11-23 KR KR1020137015172A patent/KR101838326B1/ko not_active Expired - Fee Related
- 2011-11-23 NZ NZ610700A patent/NZ610700A/en not_active IP Right Cessation
- 2011-11-23 UA UAA201307746A patent/UA109295C2/uk unknown
- 2011-11-23 MY MYPI2013001836A patent/MY168283A/en unknown
-
2013
- 2013-05-13 MA MA35892A patent/MA34658B1/fr unknown
- 2013-05-21 IL IL226495A patent/IL226495A/en active IP Right Grant
-
2014
- 2014-08-15 US US14/460,951 patent/US9156834B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502268A5 (enExample) | ||
| RU2013126251A (ru) | Производные гетероарилсульфонамидов, их получение и применение для лечения человека | |
| JP2007501264A5 (enExample) | ||
| DK2185515T3 (en) | DERIVATIVES OF 1-PHENYL-2-PYRIDINYLALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | |
| JP2014526500A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| NZ592297A (en) | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents | |
| JP2004504301A5 (enExample) | ||
| CA2526228A1 (en) | Quinoline derivatives as phosphodiesterase inhibitors | |
| HRP20141190T1 (hr) | Disupstituirani derivati piridina kao antikancerogena sredstva | |
| JP2010053153A (ja) | Ｃｂ１受容体拮抗剤の経口用医薬組成物 | |
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
| WO2005087729A1 (en) | 5-hydroxyindole-3-carboxylates derivatives and their use | |
| JP2008536825A5 (enExample) | ||
| JPH07506346A (ja) | ピペリジニルチア環状誘導体類 | |
| JP2007519659A5 (enExample) | ||
| JP2007506703A5 (enExample) | ||
| EP2621916A1 (en) | Benzazole derivatives as histamine h4 receptor ligands | |
| JP2014510695A5 (enExample) | ||
| JP2008513405A5 (enExample) | ||
| JP2007506749A5 (enExample) | ||
| NO20084691L (no) | Piperidinerivater som er nyttige for bahandling av osteoarttitt og osteoartrose | |
| RU2007121222A (ru) | Производные гидантоина, полезные в качестве ингибиторов металлопротеиназ | |
| WO2005085201A1 (ja) | 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物 |